Work

A phase II trial of TPIV200 (a polypeptide vaccine against folate receptor alpha) plus durvalumab (anti-PD-L1 antibody) in patients with platinum-resistant ovarian cancer

Year: 2018

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2018.04.124

Authors: O. Yeku, D. Zamarin, J. Gallagher, C.A. Aghajanian, J. Konner

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2810162268

FWCI: 1.126

Cites:

Cited by: 5

Related to: 10